Related Experiment Video
Updated: May 16, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system
Yi-Ping Li1, Santseharay Ramirez, Sanne B Jensen
1Copenhagen Hepatitis C Program, Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, DK-2650 Hvidovre, Denmark.
Insights
Researchers developed a new cell culture system for hepatitis C virus (HCV) genotype 1a, crucial for advancing antiviral drug and vaccine development against this difficult-to-treat infection.
Area of Science:
- Virology
- Hepatology
- Infectious Diseases
Background:
- Chronic hepatitis C virus (HCV) infection, particularly genotype 1, is a leading cause of end-stage liver disease and challenging to treat.
- Previous efforts to culture diverse HCV genotypes in vitro were limited, hindering drug and vaccine development.
- A breakthrough involved identifying mutations (LSG) enabling culture of HCV genotypes 2a and 2b.
Purpose of the Study:
- To establish a highly efficient cell culture system for genotype 1a HCV.
- To facilitate research into HCV pathogenesis, treatment, and vaccine development.
Main Methods:
- Engineered a full-length genotype 1a (TN strain) HCV genome incorporating specific mutations (LSG, NS3, NS4B, NS5B).
- Utilized Huh7.5 cells for viral replication and production.
- Assessed viral infectivity and susceptibility to antiviral agents.
Main Results:
- Developed an infectious genotype 1a HCV culture system (TNcc) with 8 mutations, achieving high viral titers (∼5 log(10) FFU/mL).
- TNcc viruses replicated efficiently and did not require further adaptation after passaging.
- Infection with TNcc was dose-dependently inhibited by interferon-alpha and direct-acting antivirals targeting HCV protease, NS5A, and NS5B.
Conclusions:
- The established genotype 1a HCV culture system is a significant advancement for HCV research.
- This system will accelerate the development of novel therapeutics and vaccines against genotype 1 HCV.
- The methodology may enable culture of other HCV isolates, aiding personalized treatment strategies.
Abstract:
Chronic infection with hepatitis C virus (HCV) is an important cause of end stage liver disease worldwide. In the United States, most HCV-related disease is associated with genotype 1 infection, which remains difficult to treat. Drug and vaccine development was hampered by inability to culture patient isolates representing HCV genotypes 1-7 and subtypes; only a recombinant 2a genome (strain JFH1) spontaneously replicated in vitro. Recently, we identified three mutations F1464L/A1672S/D2979G (LSG) in the nonstructural (NS) proteins, essential for development of full-length HCV 2a (J6) and 2b (J8) culture systems in Huh7.5 cells. Here, we developed a highly efficient genotype 1a (strain TN) full-length culture system. We initially found that the LSG substitutions conferred viability to an intergenotypic recombinant composed of TN 5' untranslated region (5'UTR)-NS5A and JFH1 NS5B-3'UTR; recovered viruses acquired two adaptive mutations located in NS3 and NS4B. Introduction of these changes into a replication-deficient TN full-length genome, harboring LSG, permitted efficient HCV production. Additional identified NS4B and NS5B mutations fully adapted the TN full-length virus. Thus, a TN genome with 8 changes (designated TN cell-culture derived, TNcc) replicated efficiently and released infectious particles of ∼5 log(10) focus-forming units per mL; passaged TNcc did not require additional changes. IFN-α and directly acting antivirals targeting the HCV protease, NS5A, and NS5B, each inhibited full-length TN infection dose-dependently. Given the unique importance of genotype 1 for pathogenesis, this infectious 1a culture system represents an important advance in HCV research. The approach used and the mutations identified might permit culture development for other HCV isolates, thus facilitating vaccine development and personalized treatment.
